Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's 'Two Sessions': Vaccines, Drugs Seen Key To Easing Restrictions Amid New Spike

Boosters Needed But mRNA Options Lag

Executive Summary

The latest policies from Beijing show that the Chinese government is readying its own new vaccines and drugs for COVID-19 in a bid to gradually ease some of the strictest pandemic restrictions globally, but progress is mixed and domestic reported infections are surging to their highest level since March 2020.

You may also be interested in...



China OKs Heterologous Booster Shots Amid Heated COVID Vaccine Race

CanSino and Zhifei have received the regulatory green light for their respective COVID-19 booster shots in China and an estimated $1.3bn vaccine market is now up for grabs. Domestic contenders are set to elbow each other in the sector with a range of viral vector, recombinant protein and mRNA-based jabs.

Hong Kong Issues Vaccine Mandate Amid Local Surge

Hong Kong is having to take drastic new measures, including a vaccine mandate, to fight a rapid surge in COVID-19 cases amid its strict "COVID zero" policies, which might signal potential challenges in the mainland. Meanwhile, US mRNA vaccine developer Moderna has announced an expansion in Asia.

How Paxlovid Approval May Influence China's Pandemic Policies

In a surprise move, China has conditionally approved Pfizer’s oral COVID-19 antiviral Paxlovid, a development that may have far-reaching consequences for the country's pandemic policies and domestic drug developers. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel